Cargando…
Bosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review
Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.
Autores principales: | Liu, Qiuying (Selina), Ass'ad, Nour Ali, Arana Yi, Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145267/ https://www.ncbi.nlm.nih.gov/pubmed/34094551 http://dx.doi.org/10.1002/ccr3.3164 |
Ejemplares similares
-
Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity
por: Moguillansky, Natalia I., et al.
Publicado: (2017) -
A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib
por: Seegobin, Karan, et al.
Publicado: (2017) -
Interstitial Lung Disease after Pleurodesis for Malignant Pleural Effusion
por: Yokoe, Norihito, et al.
Publicado: (2017) -
Bilateral pleural effusion and interstitial lung disease as unusual manifestations of kikuchi-fujimoto disease: case report and literature review
por: Garcia-Zamalloa, Alberto, et al.
Publicado: (2010) -
Bosutinib-induced lung injury: a report of two cases and literature review
por: Watanabe, Naoki, et al.
Publicado: (2022)